Principal Financial Group Inc. boosted its stake in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 5.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 50,442 shares of the company’s stock after buying an additional 2,740 shares during the period. Principal Financial Group Inc.’s holdings in Medpace were worth $24,222,000 as of its most recent SEC filing.
A number of other hedge funds also recently added to or reduced their stakes in MEDP. Geneos Wealth Management Inc. grew its position in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares during the last quarter. Steigerwald Gordon & Koch Inc. acquired a new stake in shares of Medpace in the 4th quarter worth about $30,000. Elyxium Wealth LLC bought a new stake in Medpace in the 4th quarter valued at about $30,000. Quarry LP bought a new stake in Medpace in the 3rd quarter valued at about $35,000. Finally, Bayban bought a new stake in Medpace in the 4th quarter valued at about $44,000. 77.98% of the stock is currently owned by institutional investors.
Insiders Place Their Bets
In related news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the transaction, the general counsel directly owned 20,343 shares of the company’s stock, valued at $9,154,350. The trade was a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 20.50% of the stock is owned by corporate insiders.
Medpace Price Performance
Medpace (NASDAQ:MEDP – Get Free Report) last issued its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The company had revenue of $706.60 million for the quarter, compared to analysts’ expectations of $697.82 million. During the same period last year, the firm earned $3.67 EPS. The firm’s revenue for the quarter was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities analysts expect that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
MEDP has been the subject of several recent analyst reports. Wall Street Zen cut shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Mizuho lifted their price target on Medpace from $495.00 to $586.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Barclays reduced their price objective on Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a research report on Friday, April 24th. Royal Bank Of Canada decreased their price objective on Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a report on Friday, April 24th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Medpace in a research report on Thursday, July 2nd. Two analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Medpace presently has an average rating of “Hold” and a consensus target price of $469.50.
View Our Latest Stock Report on Medpace
About Medpace
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Featured Stories
- Five stocks we like better than Medpace
- The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence
- Is Domino’s Stock Serving Up a Buying Opportunity?
- A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free
- Why Gold Miners Could Be the Market’s Biggest Comeback Story
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
